IL-PROJECT44
14.9.2021 10:32:07 CEST | Business Wire | Press release
project44 , the leader in real-time supply chain visibility and a Google Premier Visibility Provider, today announced a new partnership with Google Cloud to provide customers with better, real-time visibility into their supply chains. Under this partnership, project44 will be the first strategic partner for real-time transportation visibility to integrate its capabilities into Google Cloud’s Supply Chain Twin solution to provide joint customers with a view into the supply chain network, including data across all modes, existing integrations at scale, and strong relationships with other partners included in the offering.
“We’re excited to team up with project44 as the first strategic partner for real-time visibility in Google Cloud’s Supply Chain Twin solution. project44’s broad visibility network, workflow automation and predictive analytics enable collaboration across all facets of the supply chain,” said Hans Thalbauer, managing director, global supply chain and logistics industry solutions for Google Cloud. “project44’s incredible expertise in transportation provides customers with the technology needed to greatly improve insight into shipments and orders across their supply chain.”
Google Cloud supply chain solutions, particularly the Supply Chain Twin, deliver end-to-end visibility by bringing together data from various business systems such as enterprise resource planning (ERP), transportation management systems (TMS), and warehouse management systems (WMS), as well as data from the operational systems of the customer and those of their partners. The increased transportation visibility and reporting provided by project44 will provide customers with visibility into data relating to shipments once they have left suppliers, as well as when inventory is moving between warehouses and manufacturing plants, and into customers’ hands.
The project44 Platform currently supports more than 680 global shippers and logistics service providers, providing visibility into a network of more than 113,500 multimodal carrier integrations and 2.6M assets – the largest carrier network available in a single platform today.
“It’s incredibly validating to be selected as the first strategic visibility partner for Google Cloud and its new Supply Chain Twin solution,” said Jett McCandless, CEO and founder of project44. “Taking an integrated, data-first approach to solving the world’s most complex supply chain challenges will have significant benefits for customers who rely on accurate, real-time data to deliver outstanding experiences for their own customers.”
A Partnership for Growth
project44 is the fastest growing SaaS platform for real-time, end-to-end transportation visibility. Integrating with Google Cloud’s Supply Chain Twin is the latest step in project44’s aggressive plans which focus on organic growth, strategic acquisitions and partnerships, and geographic expansion. Having project44 data on Google Cloud’s BigQuery builds on their shared vision of highly available access to data and data-led decision making to improve operations as both customer expectations and supply chain disruptions keep rising.
Named as a Leader in the 2021 Gartner Magic Quadrant for Real-time Transportation Visibility , project44 continues to invest in platform, ecosystem and data science capabilities that deliver the most complete end-to-end supply chain visibility. The company announced record growth in Q2, including enterprise net dollar retention of 129% and 123% year-over-year growth in ARR. Already the largest visibility platform company as measured by ARR, customer count, and carriers, project44’s ARR in Q2 was more than the sum of the next top six visibility companies combined for the same quarter.
For more information on the Google Cloud Supply Chain Twin powered by project44, click here .
About project44
project44 is the world’s leading advanced visibility platform for shippers and logistics service providers. project44 connects, automates and provides visibility into key transportation processes to accelerate insights and shorten the time it takes to turn those insights into actions. Leveraging the power of the project44 cloud-based platform, organizations increase operational efficiencies, reduce costs, improve shipping performance, and deliver an exceptional experience to their customers. Connected to thousands of carriers worldwide and having comprehensive coverage for all ELD and telematics devices on the market, project44 supports all transportation modes and shipping types, including Air, Parcel, Final-Mile, Less-than-Truckload, Volume Less-than-Truckload, Groupage, Truckload, Rail, Intermodal, and Ocean. In 2021, project44 was named a Leader among Real-Time Transportation Visibility Providers in Gartner’s Magic Quadrant. To learn more, visit project44.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210914005253/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom